Transgenic mice expressing the sequences coding for the envelope proteins of the hepatitis B virus (HBV) in the liver have been used as a model of the HBV chronic carrier state. We evaluated the possibility of inducing a specific immune response to the viral envelope antigens and thus potentially controlling chronic HBV infection. Using HBV-specific DNA-mediated immunization in this transgenic model, we show that the immune response induced after a single intramuscular injection of DNA resulted in the complete clearance of circulating hepatitis B surface antigen and in the long-term control of transgene expression in hepatocytes. This response does not involve a detectable cytopathic effect in the liver. Adoptive transfer of fractionated primed spleen cells from DNA-immunized mice shows that T cells are responsible for the down-regulation of HBV mRNA in the liver of transgenic mice. To our knowledge, this is the first demonstration of a potential immunotherapeutic application of DNA-mediated immunization against an infectious disease and raises the possibility of designing more effective ways of treating HBV chronic carriers.
Hepatitis B virus (HBV) is the most common etiologic agent for infectious liver disease. Following initial infection, some individuals fail to resolve their infection and thereby become chronic carriers. The proportion of HBV-infected persons proceeding to the chronic carrier state is 5-20% of those infected as adults and as high as 95% with perinatal transmission such as occurs in areas where HBV is endemic. There are estimated to be more than 250 million chronic HBV carriers in the world today and there is a significant association between persistent infection and liver cirrhosis or hepatocellular carcinoma (1) . The control of HBV infection is thought to be mediated by both humoral and cellular immune responses involving neutralizing antibodies as well as class I and class II major histocompatibility complex (MHC)-restricted T cells (2) (3) (4) . Patients who successfully clear the virus following acute infection mount a multispecific polyclonal immune response to several HBV antigens, whereas those who remain persistently infected develop only a weak and more restricted antiviral response (5) (6) (7) (8) (9) . In infected newborns, a diminished antiviral immune response that may be due to neonatal tolerance mechanisms (see ref. 10 ) probably plays an important role in viral persistence. In chronically infected patients empty viral particles carrying the HBV surface antigen (HBsAg) are produced and secreted in large amounts by the hepatocytes, whether or not the virus replicates in the liver. These particles persist in the serum and the corresponding HBsAg-specific neutralizing antibodies (anti-HBs) are either not induced or remain undetectable by conventional techniques due to the formation of immune complexes (11) .
We have used transgenic (Tg) mice that constitutively express the HBsAg (12) as a model of chronic HBV carriers to study the possibility of inducing an immune response to HBsAg and thus control the infection. The transgene in these mice consists of a copy of the HBV genome with the core gene deleted. The sequences encoding the small, middle, and large HBV envelope proteins under the control of an endogenous HBV promoter are expressed principally in the liver from before birth (13) . As a consequence, the serum contains 200-9000 ng/ml of HBsAg, but there is no accumulation of HBsAg within hepatocytes or liver pathology. We have previously shown that B-cell nonresponsiveness can be overcome in these mice by immunization with recombinant HBsAg particles in Freund's adjuvant (14) . These findings provided the rationale for a pilot clinical study, in which we have demonstrated that specific vaccine therapy by standard anti-HBV vaccination can reduce HBV replication and circumvent nonresponsiveness to circulating HBsAg in half of the chronic carrier subjects (15) .
DNA-mediated immunization has been shown to be an effective way to induce both humoral and cell-mediated immune responses against many different antigens (for reviews, see refs. 16 and 17) including HBsAg (18) (19) (20) . In the experiments described here, we have investigated the potential of this approach for immunotherapy of chronic HBV carriers using the HBsAg transgenic mouse as a model. We show that this novel method of immunization is able to overcome functional tolerance to HBsAg and to control transgene expression by a mechanism that does not involve a detectable cytopathic effect on the liver.
MATERIALS AND METHODS
Mice. The generation and characterization of the HBV envelope transgenic mouse lineage E36 have been previously reported (12, 13) . These mice were produced on a C57BL/6 x SJL/J background and were back crossed against C57BL/6 (H-2b) at least 15 times before use. Only female mice, [5] [6] [7] [8] weeks old, heterozygous for the HBV envelope transgene and their nontransgenic littermates were used. All experiments involving mice were carried out in accordance with institutional guidelines.
DNA Immunization. Each mouse was injected on a single occasion with 100 ,ug recombinant plasmid DNA expressing the S and pre-S2 domains of the gene encoding the HBV envelope protein (pCMV-S2.S) (20) or the Escherichia coli LacZ gene encoding ,B-galactosidase (13-gal) (pCMV-LacZ) (21) . The DNA was purified by anion-exchange chromatography (Qiagen, Hilden, Germany) and was injected directly into regenerating tibialis anterior muscles as described (22) .
Serology. Blood was collected from anesthetized mice by retrobulbar puncture using heparinized glass pipettes and HBsAg was measured in the plasma using a commercial ELISA kit (Monolisa AgHBs; Diagnostics Pasteur, Marnes la Coquette, France). Quantitation of mouse anti-HBs antibody was performed by an ELISA using purified recombinant particles of the same subtype (ayw) with or without the middle HBV envelope protein (14) . For isotype determination, serial dilutions of plasma from immunized mice were added to HBsAg-coated wells (1 ,ug/ml) and bound antibodies were detected by anti-mouse subclass-specific biotinylated antibodies followed by streptavidin-horseradish peroxidase staining (Amersham). Antibody titers were determined by the serial end-point dilution method. The end-point was defined as the highest serum dilution that resulted in an absorbance value two times greater than that of nonimmune or control serum, with a cutoff value of 0.05. Serum alanine aminotransferase activity in the plasma was measured using a commercial kit (Enzyline; BioMerieux, Marcy P'etoile, France).
Histological Procedures. Tissues were fixed in alcoholic Bouins' fixative. Sections of paraffin-embedded tissues were cut at 5 ,um thickness and stained with hematoxylin/eosin and trichrome.
Northern Blot Analysis. Total RNA of liver was extracted from mechanically pulverized frozen tissue by the hot-phenol procedure (13 (18, 20) . Injection of a vector encoding the small and the middle forms of HBV envelope protein (pCMV-S2.S) into normal mice induced a strong and long-lasting humoral response to the preS2 domain of the middle protein and to subtype-and group-specific HBsAg determinants (20) .
A single injection of this pCMV-S2.S DNA into HBsAgtransgenic mice provoked a decrease in the levels of circulating HBsAg ( Fig. 1 ) and the concomitant appearance of anti-HBs antibodies which increased over time (Fig. 2) . In some ofthe mice, antigen was eliminated from the serum as early as 4 weeks after injection of the DNA and in all the mice remained undetectable for at least 12 weeks without further injections of DNA. These effects were not due to nonspecific immune stimulation induced by the injection procedure or the presence of DNAper se, since HBsAg levels were unaffected ( Fig. 1 ) and no anti-HBs was detected ( Free antibodies, which were first detectable in the plasma of Tg mice 2-4 weeks following injection of pCMV-S2.S DNA, were initially preS2-specific since they reacted only with particles carrying this epitope but not with particles devoid of it (Fig. 2) . Antibodies against S-specific epitopes were not observed until 8 weeks, at which time there was a complete clearance ofcirculating HBsAg (see Fig. 1 ). It is clear that, even though Tg mice demonstrate high levels of circulating HBsAg from before birth (13), DNA-based immunization was able to induce titers of anti-HBs comparable to those induced in non-Tg controls and that these antibodies were able to completely neutralize the circulating HBsAg. The isotype profile of the anti-HBs antibodies determined at the time of Tg mice seroconversion (12 weeks) was identical in Tg and in non-Tg mice and included IgG2a and IgG2b as well as IgGl with some IgG3 (Fig. 3) . The presence of these isotypes indicates that DNA-mediated immunization triggered CD4+ T-helper (Th) cells.
To further characterize the T-helper subset, we analyzed cytokine production from spleen cells in culture at the time of initiation of the immune response. Spleens were removed from mice at 2 weeks after DNA injection and cell suspensions were specifically stimulated in vitro with HBsAg particles or preS2 peptide. The cytokine profile was identical for immunized Tg and non-Tg mice. These cultures produced IFN--y and TNF-a, but no detectable IL-4 ( Table 1 ). The presence of IgG2a antibodies and of IFN-y-secreting spleen cells is consistent with a ongoing Thl response; however, detection of IgGl at the later times (12weeks) suggests that a Th2 response has also been induced.
Assessment of Liver Cell Injury. To assess the effect of DNA immunization on the liver, the serum level of transaminases were measured after injection of DNA at the times indicated on Fig.  1 , when the sera where taken for detection of anti-HBs. The rapid clearance of circulating antigen from immunized mice did not appear to result from a significant or persistent HBsAg-specific cytopathic effect on the liver since levels of transaminase activity in the plasma remained normal subsequent to injection of DNA. Furthermore, histological analysis of the liver was carried out at 12 and 20 weeks after DNA injection when HBsAg was cleared in all mice. Microscopic examination of liver sections showed no evidence of necrosis or inflammation.
Regulation of Transgene Expression. Since the persistent clearance of the transgene product was not associated with any apparent destruction of the transgene-expressing liver cells, we evaluated the HBV mRNA content in the livers of Tg mice. At 12 weeks after immunization with pCMV-S2.S, the mRNA was decreased in the livers of those mice which had partially cleared the antigen, and was undetectable in those which had completely eliminated HBsAg from their sera (Fig. 4A , lanes 5 and 6-7, respectively). This effect is persistent since HBV mRNA remained undetectable in the livers of mice analyzed 20 weeks after DNA injection (Fig. 4A, lanes 8 and 9) . In contrast, HBV mRNA was not diminished in livers taken from Splenocytes of pCMV-S2.S-immunized Tg and non-Tg mice were incubated with medium or stimulated with concanavalin A (ConA; 2.5 A.g/ml), preS2 peptide (10 ,tg/ml), or HBsAg particles (3 ,ug/ml) for 72
hr. Antigen-specific culture supernatants were harvested for determination of cytokine levels (pg/ml) at 24 hr for TNF-a and IL-2 determinations and at 48 hr for IFN-,y and IL-4. Data are as the arithmetic mean ± SEM of 5-6 spleens independently tested in two experiments. untreated Tg mice or Tg mice which had been injected with pCMV-LacZ DNA (Fig. 4A, lane 1 and lanes 2-4, respectively) . This indicates that the inhibition of viral gene expression in Tg mice injected with pCMV-S2.S was not due to a nonspecific effect such as the release of cytokines with injection-induced inflammation and/or with an immune response against transfected muscle cells expressing a foreign antigen (i.e., 13-gal). Thus, the HBsAg-specific immune response induced by immunization with plasmid DNA appears to be responsible for controlling hepatic transgene expression by some noncytopathic mechanism.
To determine which component of the immune response is implicated in the down-regulation of HBV-specific mRNA and in the observed decrease or elimination of the circulating antigen, we performed adoptive transfer experiments. Fully immunocompetent non-Tg mice were immunized once with the pCMV-S2.S DNA vector and when ELISA titers of serum antibodies to HBsAg had reached at least 104, both the serum and the primed spleen cells were harvested from the mice for transfer into their Tg littermates. Passive transfer of serum-derived antibodies on a single occasion into Tg mice induced a rapid but transient decrease in circulating HBsAg levels (mice 2-21 and 4-26, Table 2 ). In other Tg mice, circulating antigen was maintained at undetectable levels for a longer period by intraperitoneal injection of hyperimmune sera every 2-3 days over a period of 17 days (mice 1-3-5 and 1-3-6, Table 2 ). Neither single nor chronic administration of antibodies resulted in decreased HBVspecific mRNA in the liver (not shown), indicating that the humoral response after DNA-based immunization was not responsible for the down-regulation of transgene expression or the long-term elimination of the transgene product. Injection of primed spleen cell suspensions obtained from pCMV-S2.S immunized non-Tg donor mice into Tg littermate recipients resulted in a rapid clearance of circulating HBsAg (by 7 days) along with a concomitant and sustained appearance of anti-HBs antibodies (Fig. 5) . This indicates that the transferred B cells were activated in the Tg mice, probably by the circulating antigen. In contrast, injection of /3-gal-primed spleen cells into Tg recipients had no effect on the level of serum HBsAg (Fig. 5) . Adoptive transfer of HBsAg-but not 3-gal-primed spleen cells was also able to induce a complete disappearance of HBV mRNA in the liver by 17 days (Fig. 6 and Fig. 4B, lanes 4 and 5, and 2 and 3, respectively) . Serum HBsAg became undetectable 10 days prior to the disappearance of HBV mRNA (Fig. 6) , suggesting that two separate mechanisms may be responsible for the observed clearance of the antigen: an initial transient elimination due to formation of immune complexes and a subsequent more permanent control of transgene transcription.
Serum transaminase activity and histological examination of liver sections were monitored every 2-3 days after adoptive transfer and found to be normal for up to 17 days, after which some histological sections of liver exhibited a few small necrotic foci. These were sometimes accompanied by the presence of inflammatory cells, but in no case did the necrotic regions involve more than 5% of the hepatic cells. In addition, a few apoptotic hepatocytes were detected in centrilobular areas within some randomly distributed lobules (not shown).
T Cells Are Able to Control Transgene Expression in the Absence of Antibody Production. To determine which spleen cell population was involved in the decrease or disappearance of circulating HBsAg and liver HBV mRNA, we carried out adoptive transfer with fractionated B-or T-spleen cells obtained from non-Tg donor mice immunized with pCMV-S2.S. After depletion of T cells, the transfer of HBsAg-primed spleen cells into Tg mice did not induce anti-HBs and had no effect on levels of circulating HBsAg or liver HBV mRNA (Fig. 4B, lane 6) . This indicates that production of antibody detected in DNA-immunized Tg mice is dependent on an exogenous T-cell help (see Fig. 2 ). In contrast, transfer of B-cell-depleted spleen cells resulted in clearance of circulating HBsAg within 14-17 days although antibody to HBsAg was not detected in these recipient mice at these times (not shown). Thus, antigen-antibody complex formation is not required for, but has a synergistic effect on the elimination of circulating antigen (Fig. 5 ). It appears nonetheless that HBsAg-specific T cells are responsible for down-regulation of transgene expression since transfer of only primed T cells but not B cells or unprimed T-cells was able to reduce HBV mRNA in the liver to undetectable levels (Fig. 4B, lanes 6-9) (31) have reported that passive transfer of HBsAg-specific CD8+ CTL clones, which secreted IFN-,y and TNF-a, caused only a limited cytopathic response in the liver, but that this in turn activated a complex regulatory cascade which transiently inhibited transgene expression in the remaining liver cells without killing them. In the present study, using plasmid DNA for immunization, clonal expansion of HBsAg-specific T cells, either CD4+ Thl or CD8+ CTLs or both might be the effector cells responsible for the downregulation of HBV mRNA in the Tg liver cells via secretion of IFN-,y or other cytokines. In this Tg model the immune response induced by a single injection of DNA was remarkably well balanced between antibody production, which probably facilitated antigen clearance, and induction of HBsAg-specific T cells, which regulated transgene expression. These responses, which-persisted for at least 5 months without further DNA injections, could be ascribed to the long-lasting immunity induced by DNA-based immunization (20, 32) .
During HBV infection in humans, a T-helper-dependent B-cell response directed toward envelope determinants is required for clearance of the circulating particles (2) . In some chronic carriers of HBV, the absence of anti-HBs production and of a CTL response could be due to a lack of helper function from H4BV-specific CD4+ T cells, which are found in all patients who successfully clear the virus but not in those who remain chronically infected (5). Thus, in some individuals with chronic hepatitis, there 
